{
  "id": 19323819,
  "title": "FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know",
  "url": "https://urgent.news/2026/11/10/fda-flags-potential-vision-loss-risk-linked-to-glp-1-drugs-what-users",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T10:18:26.000Z",
  "source": {
    "name": "Live Mint",
    "slug": "live-mint",
    "url": "https://www.livemint.com/news/us-news/fda-flags-potential-vision-loss-risk-linked-to-glp-1-drugs-what-users-of-weight-loss-medications-should-know-11794304730495.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 drug users than among those taking placebos or other diabetes medications.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}